Search Results - "De Jesus‐Acosta, Ana"

The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience by Moningi, Shalini, Dholakia, Avani S., Raman, Siva P., Blackford, Amanda, Cameron, John L., Le, Dung T., De Jesus-Acosta, Ana M. C., Hacker-Prietz, Amy, Rosati, Lauren M., Assadi, Ryan K., Dipasquale, Shirl, Pawlik, Timothy M., Zheng, Lei, Weiss, Matthew J., Laheru, Daniel A., Wolfgang, Christopher L., Herman, Joseph M.

“…Background Stereotactic body radiation therapy (SBRT) is a promising option for patients with pancreatic cancer (PCA); however, limited data support its…”
Get full text

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer by Yarchoan, Mark, Huang, Chiung‐Yu, Zhu, Qingfeng, Ferguson, Anna K., Durham, Jennifer N., Anders, Robert A., Thompson, Elizabeth D., Rozich, Noah S., Thomas, Dwayne L., Nauroth, Julie M., Rodriguez, Christina, Osipov, Arsen, De Jesus‐Acosta, Ana, Le, Dung T., Murphy, Adrian G., Laheru, Daniel, Donehower, Ross C., Jaffee, Elizabeth M., Zheng, Lei, Azad, Nilofer S.

“…Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory to single‐agent programmed cell death protein 1 (PD1) inhibitor…”
Get full text

Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta‐analysis of real‐world evidence by Gupta, Amol, Jesus‐Acosta, Ana, Le, Dung, Pishvaian, Michael, Zaidi, Neeha, Zheng, Lei, Laheru, Daniel

“…Background Pivotal clinical trials supported survival benefits of liposomal irinotecan (nal‐IRI) plus fluorouracil/leucovorin in patients with pancreatic…”
Get full text

The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy by Bever, Katherine M, Sugar, Elizabeth A, Bigelow, Elaine, Sharma, Rajni, Laheru, Daniel, Wolfgang, Christopher L, Jaffee, Elizabeth M, Anders, Robert A, De Jesus-Acosta, Ana, Zheng, Lei

“…Abstract Background Pancreatic ductal adenocarcinoma (PDA) is comprised of a prominent desmoplastic stromal compartment and only 10–40% of the tumour consists…”
Get full text

High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy by Hill, Colin, Sehgal, Shuchi, Fu, Wei, Hu, Chen, Reddy, Abhinav, Thompson, Elizabeth, Hacker‐Prietz, Amy, Le, Dung, De Jesus‐Acosta, Ana, Lee, Valerie, Zheng, Lei, Laheru, Daniel A., Burns, William, Weiss, Matthew, Wolfgang, Christopher, He, Jin, Herman, Joseph M., Meyer, Jeffrey, Narang, Amol

“…Background Stereotactic body radiation therapy (SBRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma (BRPC/LAPC)…”
Get full text

Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer by GUPTA, Sonal, PRAMANIK, Dipankar, MAITRA, Anirban, MUKHERJEE, Radha, CAMPBELL, Nathaniel R, ELUMALAI, Sathyanarayanan, DE WILDE, Roeland F, HONG, Seung-Mo, GOGGINS, Michael G, JESUS-ACOSTA, Ana De, LAHERU, Daniel

“…To identify a predictive molecular "signature" for sensitivity to retinoic acid in pancreatic cancer. Fourteen patient-derived, low-passage pancreatic ductal…”
Get full text

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study by O'Malley, David M, Bariani, Giovanni Mendonca, Cassier, Philippe A, Marabelle, Aurelien, Hansen, Aaron R, De Jesus Acosta, Ana, Miller, Jr, Wilson H, Safra, Tamar, Italiano, Antoine, Mileshkin, Linda, Xu, Lei, Jin, Fan, Norwood, Kevin, Maio, Michele

“…Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability-high or mismatch…”
Get full text

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival by Özdemir, Berna C., Pentcheva-Hoang, Tsvetelina, Carstens, Julienne L., Zheng, Xiaofeng, Wu, Chia-Chin, Simpson, Tyler R., Laklai, Hanane, Sugimoto, Hikaru, Kahlert, Christoph, Novitskiy, Sergey V., De Jesus-Acosta, Ana, Sharma, Padmanee, Heidari, Pedram, Mahmood, Umar, Chin, Lynda, Moses, Harold L., Weaver, Valerie M., Maitra, Anirban, Allison, James P., LeBleu, Valerie S., Kalluri, Raghu

“…Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal myofibroblasts, but their functional contribution remains unknown…”
Get full text

Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer by Shrestha, Bikram, Sun, Yifei, Faisal, Farzana, Kim, Victoria, Soares, Kevin, Blair, Alex, Herman, Joseph M., Narang, Amol, Dholakia, Avani S., Rosati, Lauren, Hacker‐Prietz, Amy, Chen, Linda, Laheru, Daniel A., De Jesus‐Acosta, Ana, Le, Dung T., Donehower, Ross, Azad, Nilofar, Diaz, Luis A., Murphy, Adrian, Lee, Valerie, Fishman, Elliot K., Hruban, Ralph H., Liang, Tingbo, Cameron, John L., Makary, Martin, Weiss, Matthew J., Ahuja, Nita, He, Jin, Wolfgang, Christopher L., Huang, Chiung‐Yu, Zheng, Lei

“…The use of neoadjuvant chemotherapy or radiation for borderline resectable pancreatic adenocarcinoma (BL‐PDAC) is increasing. However, the impact of…”
Get full text

Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After 177Lu-DOTATATE Therapy by Voter, Andrew F, Gafita, Andrei, Werner, Rudolf A, Jesus-Acosta, Ana De, Rowe, Steven P, Solnes, Lilja B

“…177Lu-DOTATATE is an effective second-line treatment for metastatic or nonresectable neuroendocrine tumors. This treatment can result in hematologic severe…”
Get full text

Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma by De Jesus-Acosta, Ana, Sugar, Elizabeth A., O’Dwyer, Peter J., Ramanathan, Ramesh K., Von Hoff, Daniel D., Rasheed, Zeshaan, Zheng, Lei, Begum, Asma, Anders, Robert, Maitra, Anirban, McAllister, Florencia, Rajeshkumar, N. V., Yabuuchi, Shinichi, de Wilde, Roeland F., Batukbhai, Bhavina, Sahin, Ismet, Laheru, Daniel A.

“…Background The Hedgehog (Hh) signalling pathway is overexpressed in pancreatic ductal adenocarcinoma (PDA). Preclinical studies have shown that Hh inhibitors…”
Get full text

A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma by Heumann, Thatcher, Judkins, Carol, Li, Keyu, Lim, Su Jin, Hoare, Jessica, Parkinson, Rose, Cao, Haihui, Zhang, Tengyi, Gai, Jessica, Celiker, Betul, Zhu, Qingfeng, McPhaul, Thomas, Durham, Jennifer, Purtell, Katrina, Klein, Rachel, Laheru, Daniel, De Jesus-Acosta, Ana, Le, Dung T., Narang, Amol, Anders, Robert, Burkhart, Richard, Burns, William, Soares, Kevin, Wolfgang, Christopher, Thompson, Elizabeth, Jaffee, Elizabeth, Wang, Hao, He, Jin, Zheng, Lei

“…A neoadjuvant immunotherapy platform clinical trial allows for rapid evaluation of treatment-related changes in tumors and identifying targets to optimize…”
Get full text

Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma by Zheng, Lei, Ding, Ding, Edil, Barish H, Judkins, Carol, Durham, Jennifer N, Thomas, 2nd, Dwayne L, Bever, Katherine M, Mo, Guanglan, Solt, Sara E, Hoare, Jessica A, Bhattacharya, Raka, Zhu, Qingfeng, Osipov, Arsen, Onner, Beth, Purtell, Katrina A, Cai, Hongyan, Parkinson, Rose, Hacker-Prietz, Amy, Herman, Joseph M, Le, Dung T, Azad, Nilofer S, De Jesus-Acosta, Ana M C, Blair, Alex B, Kim, Victoria, Soares, Kevin C, Manos, Lindsey, Cameron, John L, Makary, Martin A, Weiss, Matthew J, Schulick, Richard D, He, Jin, Wolfgang, Christopher L, Thompson, Elizabeth D, Anders, Robert A, Sugar, Elizabeth, Jaffee, Elizabeth M, Laheru, Daniel A

“…Immunotherapy is currently ineffective for nearly all pancreatic ductal adenocarcinomas (PDAC), largely due to its tumor microenvironment (TME) that lacks…”
Get full text

Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity by Hill, Colin S., Rosati, Lauren M., Hu, Chen, Fu, Wei, Sehgal, Shuchi, Hacker-Prietz, Amy, Wolfgang, Christopher L., Weiss, Matthew J., Burkhart, Richard A., Hruban, Ralph H., De Jesus-Acosta, Ana, Le, Dung T., Zheng, Lei, Laheru, Daniel A., He, Jin, Narang, Amol K., Herman, Joseph M.

“…Background Patients with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) are at high risk of margin-positive…”
Get full text

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer by Yarchoan, Mark, Myzak, Melinda C, Johnson, 3rd, Burles A, De Jesus-Acosta, Ana, Le, Dung T, Jaffee, Elizabeth M, Azad, Nilofer S, Donehower, Ross C, Zheng, Lei, Oberstein, Paul E, Fine, Robert L, Laheru, Daniel A, Goggins, Michael

“…Olaparib is an oral inhibitor of polyadenosine 5'-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA…”
Get full text

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study by Gupta, Amol, De Jesus-Acosta, Ana, Zheng, Lei, Lee, Valerie, Kamel, Ihab, Le, Dung, Pishvaian, Michael, Laheru, Daniel

“…Background The efficacy of combination chemotherapy beyond the first-line setting remains modest in patients with advanced pancreatic adenocarcinoma (PAC)…”
Get full text

Health-related quality of life in patients treated with pembrolizumab for microsatellite instability–high/mismatch repair–deficient advanced solid tumours: Results from the KEYNOTE-158 study by Maio, Michele, Amonkar, Mayur M., Norquist, Josephine M., Ascierto, Paolo A., Manzyuk, Ludmila, Motola-Kuba, Daniel, Penel, Nicolas, Cassier, Philippe A., Bariani, Giovanni M., De Jesus Acosta, Ana, Doi, Toshihiko, Longo, Federico, Miller, Wilson H., Oh, Do-Youn, Gottfried, Maya, Wang, Ruixue, Norwood, Kevin, Marabelle, Aurelien

“…In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated,…”
Get full text

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition by Zhou, Wei, Jubb, Adrian M, Lyle, Karen, Xiao, Qian, Ong, Christy C, Desai, Rupal, Fu, Ling, Gnad, Florian, Song, Qinghua, Haverty, Peter M, Aust, Daniela, Grützmann, Robert, Romero, Mally, Totpal, Klara, Neve, Richard M, Yan, Yibing, Forrest, William F, Wang, Yulei, Raja, Rajiv, Pilarsky, Christian, de Jesus-Acosta, Ana, Belvin, Marcia, Friedman, Lori S, Merchant, Mark, Jaffee, Elizabeth M, Zheng, Lei, Koeppen, Hartmut, Hoeflich, Klaus P

“…Pancreatic adenocarcinoma (PDAC) is a major unmet medical need and a deeper understanding of molecular drivers is needed to advance therapeutic options for…”
Get full text

Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy by Reddy, Abhinav V, Hill, Colin S, Sehgal, Shuchi, Zheng, Lei, He, Jin, Laheru, Daniel A, Jesus-Acosta, Ana De, Herman, Joseph M, Meyer, Jeffrey, Narang, Amol K

“…To investigate the role of pre- and post-stereotactic body radiation therapy (SBRT) neutrophil-to-lymphocyte ratio (NLR) in patients with localized pancreatic…”
Get full text

Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer by Christenson, Eric S, Lee, Valerie, Wang, Hao, Yarchoan, Mark, De Jesus-Acosta, Ana, Azad, Nilo, Gurakar, Ahmet, Lin, Ming-Tseh, Le, Dung T, Brennan, Daniel C, Jaffee, Elizabeth M, Bever, Katherine

“…Solid organ transplants are associated with a modestly increased risk of colorectal cancers (CRC). However, the molecular profile of these cancers has not been…”
Get full text